Met Life Investment Management, LLC Immuneering Corp Transaction History

Met Life Investment Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 09, 2024	BUY	$7.21 - $10.68 $81,162 - $120,224	11,257 New	11,257 $86,000
Q2 2023 Apr 29, 2024	BUY	$6.49 - $13.36 $73,057 - $150,393	11,257 New	11,257 $114,000
Q2 2023 Aug 10, 2023	BUY	$6.49 - $13.36 $73,057 - $150,393	11,257 New	11,257 $114,000
Q4 2021 Feb 15, 2022	SELL	$16.12 - $31.02 $59,950 - $115,363	-3,719 Closed	0 $0
Q3 2021 May 17, 2024	BUY	$17.0 - $32.84 $63,223 - $122,131	3,719 New	3,719 $98,000
Q3 2021 Jun 21, 2023	BUY	$17.0 - $32.84 $63,223 - $122,131	3,719 New	3,719 $98,000
Q3 2021 Mar 22, 2023	BUY	$17.0 - $32.84 $63,223 - $122,131	3,719 New	3,719 $98,000
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $63,223 - $122,131	3,719 New	3,719 $99,000

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $57.8M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.